Immunomodulators Market to 2017 - Immunosuppressant Antibodies to ReplaceAntimetabolites as the Highest Value Sector by 2017
Immunosuppressants holds a 64% Market Share of the ImmunomodulatorsMarket with More Products in the Pipeline than Immunostimulants
This report provides insight about immunomodulators sales forecasts until 2017.Immunomodulators markets in the key geographies of the US, Europe and other relevantregions are also covered in the report, as are immunomodulators R&D pipelines. The reportprovides in-depth analysis and market forecasts of the major drug classes, which includeimmunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, andantimetabolites), and immunostimulants (antibodies, interferon alpha and vaccines). Thereport also explores the competitive landscape, with a competitive analysis of the topcompanies in the market.GBI Research analysis estimated the global immunomodulators market to be valued at$145.9 billion in 2010, with a Compound Annual Growth Rate (CAGR) of 13.1% between2002 and 2010. The market is forecast to grow at a CAGR of 8.6% between 2010 and 2017,to reach $259.3 billion in 2017. In-depth analysis in the report is based on proprietydatabases, primary and secondary research and in
house analysis by the GBI Researchteam of experts.GBI Research analysis found the R&D pipeline for the immunomodulators market to bestrong. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that R&D activity forimmunomodulators will remain active for at least next four to five years.
Request a Sample for or Inquire before buying the report
Price: Single User License
Corporate User License
* Data and analysis of the immunomodulators market in the leading geographies of the USand Europe. Different drug classes of immunomodulators discussed in the report areimmunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors,antimetabolites) and immunostimulants (antibodies, interferon alpha and vaccines).* Annualized market data for the immunomodulators market from 2002 to 2010, with